KRAS and pancreatic neoplasm: The ORGANOPREDICT trial further underscored the predictive power of PDO-based pharmacotyping in advanced refractory pancreas cancer, identifying effective drugs in most cases, even in heavily pretreated individuals, and validating the synergy between KRAS and ERBB inhibitors (62).